Tagmokitug not checked
Coherus Oncology, Inc. · CHS-114
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- Tested for
- Advanced Solid Tumor (2 trials), Solid Tumor, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor
- Main trialPhase 1/2
- “The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.”In the company’s words, NCT07945821 on ClinicalTrials.gov
- Other names
- CHS-114
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- Aug 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT07945821
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2028 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors | |
| Phase 1Active, not recruiting | 30 Sep 2026 | Study of CHS-114 in Participants With Advanced Solid Tumors | |
| Phase 1Recruiting | Jan 2028 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026